' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients" pretreatment status.
Weingrill, E; Wolfler, A; Strunk, D; Linkesch, W; Sill, H; Liebmann, PM
HAEMATOL-HEMATOL J. 2007; 92(9): 1286-1288.
Letter

PMU-Autor/inn/en

Strunk Dirk

Abstract

Roscovitine induced apoptosis in isolated B-chronic lymphocytic leukemia cells of 25 patients of whom nine with relapsed and seven with fludarabine-refractory disease. It was synergistic with alemtuzumab and restored sensitivity to alemtuzumab in initially alemtuzumab-resistant samples. Observed roscovitine-induced up-regulation of CD52 surface expression may be one of the underlying mechanisms for this synergism.


Useful keywords (using NLM MeSH Indexing)

Aged

Aged, 80 and over

Antibodies, Monoclonal/administration*

dosage

Antibodies, Monoclonal, Humanized

Antibodies, Neoplasm/administration*

dosage

Antigens, CD/metabolism

Antigens, Neoplasm/metabolism

Antineoplastic Combined Chemotherapy Protocols/therapeutic use*

Apoptosis/drug effects*

Cohort Studies

Drug Synergism*

Female

Glycoproteins/metabolism

Humans

Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy*

Male

Middle Aged

Mitoxantrone/administration*

dosage

Purines/administration*

dosage

Salvage Therapy


Find related publications in this database (Keywords)

B-CLL
roscovitine
alemtuzumab
apoptosis
synergism